Subscribe
Share
Share
Embed
Episode three organizes cholangiocarcinoma anatomy first, biology second, because where the tumor sits dictates the operation and the transplant path. Intrahepatic disease is resected when possible and is a transplant contraindication over two centimeters, distal disease gets a Whipple, and perihilar disease is resected when resectable with a narrow unresectable subset going through a neoadjuvant-then-transplant protocol. The imaging is delayed enhancement without washout, the mirror image of HCC, because the fibrous stroma traps contrast rather than letting it run through. CA 19-9 is a trend rather than a yes-or-no and is unusable in Lewis-negative patients, so sclerosing cholangitis patients with a new dominant stricture get FISH on the brushings when cytology fails them.
Topics covered
Key decisions
This is an AI-generated podcast, and some pronunciations may be imperfect. Thank you for your understanding, and we hope you enjoyed this content.
Study the full chapter on Board Pearls, with practice questions, tables and primary-guideline references: Liver Tumors and Transplantation
Read this episode: boardpearls.com/gi/episodes/liver-tumors-and-transplant-ep3
Questions or feedback: hello@boardpearls.com.
The most complete gastroenterology board-review podcast on the web, and it is entirely free. This is the GI series from Board Pearls: board review built around clinical reasoning, not recall. Every episode takes one high-yield topic and works it the way you would on rounds: a case to anchor it, the framework that sorts the differential, and the specific decisions the exam rewards. No trivia, no textbook dictation, just the thinking that earns the point.
Over 100 episodes span the full blueprint across nine modules (esophagus, stomach and duodenum, small bowel, colon, pelvic floor, liver, pancreas and biliary, endoscopy, and the cross-cutting topics), grouped by chapter and built from the guidelines and pivotal trials the boards are written from: ACG, AGA, AASLD, and ASGE.
Pair it with the written curriculum, question bank, and AI tutor at boardpearls.com. Questions or feedback: hello@boardpearls.com.
Welcome to Board Pearls. This is episode three of four of the Liver Tumors and Transplant chapter, in the Liver Disease module. This episode is cholangiocarcinoma, and the whole thing turns on one idea: where the tumor sits along the biliary tree makes it effectively three different diseases, with three different operations and three different transplant pathways, so the first move is to stop treating it as one cancer.
Intrahepatic cholangiocarcinoma arises inside the liver parenchyma, above the second-order bile ducts. Perihilar cholangiocarcinoma, the Klatskin tumor, arises right at the confluence where the two hepatic ducts meet. And distal cholangiocarcinoma arises down between the cystic duct and the ampulla. That split isn't academic, because location dictates the surgery.
An intrahepatic tumor comes out with the piece of liver that contains it. A perihilar tumor sits at the confluence where the anatomy is unforgiving, so its resection means taking half the liver plus the extrahepatic bile duct plus a Roux-en-Y reconstruction. And a distal tumor comes out with a pancreaticoduodenectomy, the Whipple, the same operation as for a periampullary cancer, because the distal duct and the pancreatic head share a resection plane. So if you know the location you know the operation, and if you don't, you can't even begin to reason about resectability or transplant.
Perihilar tumors get further sorted by how far the tumor climbs into the intrahepatic ducts, because that determines how much liver has to come out. The lowest type spares the confluence, the next reaches the confluence but doesn't climb into either main duct, the next two extend up into the right or the left duct respectively, and the highest involves both sides or is multifocal. This matters because the higher types require the corresponding hepatectomy, and the both-sides type often crosses into unresectable disease because no clean remnant lobe is left.
The imaging is where cholangiocarcinoma and HCC separate in a way the boards test. HCC washes out in the portal-venous phase. Intrahepatic cholangiocarcinoma does the opposite, taking up contrast progressively in the venous and delayed phases with no washout, and the reason is the dense fibrous stroma this tumor builds around itself, which traps contrast and releases it slowly, so you get delayed retention rather than the rapid clearance you see when HCC empties through its abnormal capillaries. The two cancers have opposite vascular behavior and the imaging shows it. PET has limited specificity for the primary mass, so it isn't a diagnostic test for the tumor itself, but it earns its place in staging for distant and nodal disease, because a positive distant focus flips management from curative surgery to systemic therapy. Endoscopic ultrasound helps with local staging and tissue for the perihilar and distal tumors, where you can't reach well from the abdominal wall.
The risk factors all share one mechanism, which is how to remember them: chronic biliary inflammation is the substrate that turns into cancer. Primary sclerosing cholangitis is the dominant Western risk, carrying a lifetime cholangiocarcinoma risk in the range of ten to fifteen percent, and cholangiocarcinoma is the leading cause of cancer death in that disease. Chronic hepatitis B and C drive mostly intrahepatic tumors. Stones in the ducts, choledochal cysts, and Caroli disease all set up chronic intraductal injury. Liver flukes are the dominant cause in East and Southeast Asia. And thorotrast is the historical one, an old radioactive contrast agent. Different exposures, same story: decades of biliary epithelial injury and repair driving malignant change.
The serum marker CA nineteen-nine is both used and misread. It rises in most patients with cholangiocarcinoma but it also rises in any benign biliary obstruction or cholangitis, so a high value isn't specific, and it fails in the other direction too, because a small share of people are Lewis-antigen negative and simply can't make CA nineteen-nine even with active disease, so a normal value in a Lewis-negative patient tells you nothing. What the marker is actually good for is a trend in a high-risk patient, especially a sclerosing cholangitis patient with a new dominant stricture, where a rising value alongside a changing image raises the probability of malignancy.
That patient is the recurring diagnostic problem and deserves its own sequence. Surveillance shows a new stricture at the hilum with a rising alkaline phosphatase and a rising CA nineteen-nine, imaging confirms the stricture with mild upstream dilation, and ERCP brushings come back atypical but not diagnostic. The temptation is to trend the marker for a few months, but that buys time during which a curable tumor can grow past the resection or transplant window.
The right next step is fluorescence in situ hybridization on those same brushings, which detects the chromosomal gains that carry high specificity for cholangiocarcinoma in an indeterminate stricture, so polysomy on FISH in that patient moves them toward either the transplant protocol or resection depending on location and size. The logic is that cytology has poor sensitivity in this setting and FISH adds specificity, so the combination is the most you can get out of the existing brushings without another procedure.
Now the management split. Intrahepatic cholangiocarcinoma is resected when it's resectable, and resection is the only cure, requiring an adequate liver remnant and no involvement of the major hepatic veins or the portal bifurcation. There's one rule worth stating cleanly because it inverts the usual transplant logic: intrahepatic cholangiocarcinoma larger than two centimeters is a contraindication to transplant. The reason is that post-transplant survival is poor, driven by occult micrometastatic disease that's already present at transplant even when the staging looks clean, so putting a tumor over two centimeters into a transplant under immunosuppression accelerates the metastatic disease the workup didn't see. Resection, where feasible, is the patient's best chance.
Distal cholangiocarcinoma is treated with a Whipple, because the distal duct and the pancreatic head are inseparable in the resection plane, and the margin and lymph node principles follow from that shared anatomy.
Perihilar cholangiocarcinoma is where the algorithm flips and where the boards lean. Most perihilar tumors are resected when resectable, but a narrow subset of unresectable ones qualify for transplant under a strict protocol, because perihilar transplant only works in carefully selected biology. The tumor has to be at most three centimeters in radial diameter, with no intrahepatic metastases and no lymph node involvement, and the sequence is fixed: neoadjuvant external-beam radiation with concurrent chemotherapy, then a radiation boost, then chemotherapy maintenance up until transplant, then a staging laparotomy to catch regional spread the imaging missed, and transplant last. It works because the radiation and chemotherapy sterilize the local field while the staging laparotomy filters out the patients who would recur, so the ones who pass and go on to transplant have outcomes that justify the organ.
And there's a counterintuitive rule inside it: transperitoneal biopsy of the primary tumor is contraindicated in a transplant candidate, because the biopsy tract can seed tumor cells and disqualify the patient, so diagnosis is established instead by ERCP brushings, FISH on those brushings, imaging, CA nineteen-nine, and clinical context. The biopsy that feels mandatory in most cancers is the wrong move here, and knowing why preserves transplant candidacy.
Systemic therapy comes in when disease is unresectable and not eligible for that protocol, or when it's metastatic, and the first-line regimen is gemcitabine plus cisplatin plus durvalumab, where adding the PD-L1 inhibitor to the old two-drug backbone improved survival enough to make the triplet the standard first-line for advanced biliary tract cancer, covering intrahepatic, perihilar, and distal disease as well as gallbladder cancer.
The second-line conversation is where intrahepatic disease diverges again, because two molecular subtypes have approved targeted therapy and they show up mostly in intrahepatic tumors. FGFR2 fusions are treated with an FGFR inhibitor, pemigatinib or futibatinib, that blocks the fusion-driven kinase signaling. And IDH1 mutations are treated with ivosidenib, and the mechanism is worth holding because it's testable: the mutant enzyme makes an abnormal metabolite instead of the normal one, and that metabolite poisons the enzymes that maintain normal DNA and histone methylation, so the resulting epigenetic dysregulation drives the tumor, and ivosidenib blocks the mutant enzyme, clears the abnormal metabolite, restores normal methylation, and slows growth. Together these two actionable subtypes appear in something like a quarter to a third of intrahepatic tumors, which is why the molecular workup now matters.
So the way to think about cholangiocarcinoma is anatomy first, biology second. Location tells you the operation and the transplant path: intrahepatic gets resected when possible and is a transplant contraindication over two centimeters because occult metastatic disease wrecks post-transplant survival, distal gets a Whipple, and perihilar gets resected when resectable with a narrow unresectable subset going through the neoadjuvant-then-transplant protocol. The imaging is delayed enhancement without washout, the mirror image of HCC, because the fibrous stroma traps contrast rather than letting it run through. CA nineteen-nine is a trend and not a yes-or-no, and it's unusable in Lewis-negative patients. Sclerosing cholangitis patients with a new dominant stricture get FISH on the brushings because cytology fails them. Systemic therapy is gemcitabine, cisplatin, and durvalumab first-line. And intrahepatic disease earns a molecular workup because the FGFR2 and IDH1 subtypes together pull a meaningful fraction of patients into targeted therapy.
The next episode picks up where this ends. Transplantation is the most powerful tool in liver disease, and how patients reach it is the next problem: transplant evaluation and listing with the current allocation score and its sex adjustment, the exception points for the diseases the score undervalues, the donor types from deceased to living to donation after circulatory death, the post-transplant complications and rejection patterns, and the recurrent-disease management that determines long-term survival after the graft.